News & Updates
Dr. Carl June Awarded $1 Million As 2021 Sanford Lorraine Cross Award Recipient
Tuesday, April 20, 2021
Sanford Health gave its $1 million 2021 Sanford Lorraine Cross Award to Dr. Carl June, the health system announced Tuesday, April 13. The award is given every two years to those who have conducted breakthroughs and innovations in medical science.
Dr. Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, director of the Center for Cellular Immunotherapies and director of the Parker Institute for Cancer Immunotherapy.
June was part of a team that developed a treatment that takes selected T cells, cells that recognize harmful intruders and trigger an immune response, and reprograms them to recognize and destroy leukemia cancer cells. The therapy is now named KYMRIAH by Novartis and has been approved by the Food and Drug Administration to treat acute lymphoblastic leukemia.
Dr. Carl June was honored at Philly Fights Cancer: Round 4 for his work in immunotherapy alongside Sean Parker of the Parker Institute. To read more about this award, see here from the Philadelphia Business Journal: https://www.bizjournals.com/philadelphia/news/2021/04/15/carl-june-car-t-cell-therapy-sanford-health.html
Share this post
Sanford Health gave its $1 million 2021 Sanford Lorraine Cross Award to Dr. Carl June, the health system announced Tuesday, April 13. The award is given every two years to those who have conducted breakthroughs and innovations in medical science.
Dr. Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, director of the Center for Cellular Immunotherapies and director of the Parker Institute for Cancer Immunotherapy.
June was part of a team that developed a treatment that takes selected T cells, cells that recognize harmful intruders and trigger an immune response, and reprograms them to recognize and destroy leukemia cancer cells. The therapy is now named KYMRIAH by Novartis and has been approved by the Food and Drug Administration to treat acute lymphoblastic leukemia.
Dr. Carl June was honored at Philly Fights Cancer: Round 4 for his work in immunotherapy alongside Sean Parker of the Parker Institute. To read more about this award, see here from the Philadelphia Business Journal: https://www.bizjournals.com/philadelphia/news/2021/04/15/carl-june-car-t-cell-therapy-sanford-health.html